Pharma Equity Group’s Notification from the EPO Granting Their Patent for the Drug Candidate RNX-022 - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) announced on Tuesday, March 5th, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-pharma-equity-groups-notification-from-the-epo-granting-their-patent-for-the-drug-candidate-rnx-022/